Low incidence of lymphoproliferative disease post kidney transplantation with prevalent use of alemtuzumab

Low incidence of lymphoproliferative disease post kidney transplantation with prevalent use of alemtuzumab

Introduction: It is well known that the incidence of malignancy is significantly higher in transplanted patients than in general population. The incidence of lymphoproliferative disease post-transplantation (PTLD) is approximately of 1% to 2% in kidney transplantation recipients. Objective: The main...

Full description

Bibliographic Details
Main Authors: John Fredy Nieto-Ríos, Arbey Aristizabal-Alzate, Catalina Ocampo-Kohn, Juan José Vanegas-Ruiz, Catalina Vélez-Echeverri, Lina María Serna-Higuita, Daniel Camilo Aguirre, Carlos Enrique Yepes-Delgado, Gustavo Zuluaga-Valencia
Format: Article
Language:Spanish
Published: Asociación Regional de Diálisis y Trasplantes Renales de Capital Federal y Provincia de Buenos Aires 2014-01-01
Series:Revista de Nefrología, Diálisis y Trasplante
Subjects:
enfermedad linfoproliferativa post trasplante
PTLD
trasplante renal
alemtuzumab
Online Access:http://www.revistarenal.org.ar/index.php/rndt/article/view/99

Internet

http://www.revistarenal.org.ar/index.php/rndt/article/view/99

Similar Items